Peptide
Semaglutide
Ozempic, Wegovy, GLP-1 agonist
FDA ApprovedExtensive Human DataInjection (SubQ)
Half-life
~1 week
Common dose
0.25-2.4mg/week (titrated up)
How it works
GLP-1 receptor agonist that slows gastric emptying, suppresses appetite via hypothalamic signaling, and improves insulin secretion.
Commonly used for
Fat lossBlood sugar controlAppetite suppression
Potential benefits
- 15-20% body weight reduction in clinical trials
- FDA approved for type 2 diabetes and obesity
- Reduces cardiovascular risk significantly
- Weekly injection — highest convenience among injectables
- Appetite suppression is dramatic and consistent
Risks and downsides
- Nausea, vomiting, and GI distress very common
- Muscle mass loss alongside fat loss without resistance training
- Weight returns rapidly after stopping
- Expensive — $900+/month without insurance
- Compounded versions vary widely in quality
Heads up: This is for educational purposes only and is not medical advice. Many compounds here are not FDA approved for human use. Please talk to a doctor before starting anything.
Risk level
Evidence
What you need to get started
Community experiences
Been there?
Sign in to share your experience with the community.
Loading reviews...